A Multicentered Prospective Cohort Study of Chinese IBD Patients

NCT05386290 · clinicaltrials.gov ↗

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis
Crohn Disease

Interventions

DRUG: Infliximab
DRUG: Vedolizumab
DRUG: Ustekinumab
DRUG: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)

Sponsor

Peking Union Medical College Hospital